Dr Reddys Net Worth

Dr Reddys Net Worth Analysis

Dr Reddys Target Price Consensus

Dr Reddys Target Price Projection

Dr Reddys' current and average target prices are 14.65 and 14.97, respectively. The current price of Dr Reddys is the price at which Dr Reddys Laboratories is currently trading. On the other hand, Dr Reddys' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Dr Reddys Laboratories and the information provided on this page.

Know Dr Reddys' Top Institutional Investors

Note, although Dr Reddys' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Dr Reddys' market capitalization trends

The company currently falls under 'Large-Cap' category with a total capitalization of 11.99 B.

Project Dr Reddys' profitablity

The company has Net Profit Margin of 0.17 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.2 %, which entails that for every 100 dollars of revenue, it generated $0.2 of operating income.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Dr Reddys' management efficiency

Dr Reddys Laboratories has Return on Asset of 0.1037 % which means that on every $100 spent on assets, it made $0.1037 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1853 %, implying that it generated $0.1853 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.08 in 2025. Return On Capital Employed is likely to drop to 0.11 in 2025. At this time, Dr Reddys' Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 20.1 B in 2025, whereas Other Current Assets are likely to drop slightly above 10.2 B in 2025.

Dr Reddys Corporate Filings

Dr Reddys time-series forecasting models is one of many Dr Reddys' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dr Reddys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Dr Reddys Earnings Estimation Breakdown

The calculation of Dr Reddys' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dr Reddys is estimated to be 17.3475 with the future projection ranging from a low of 17.3475 to a high of 17.3475. Please be aware that this consensus of annual earnings estimates for Dr Reddys Laboratories is based on EPS before non-recurring items and includes expenses related to employee stock options.

Dr Reddys Earnings Projection Consensus

Dr Reddys Earnings History

Earnings estimate consensus by Dr Reddys Laboratories analysts from Wall Street is used by the market to judge Dr Reddys' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Dr Reddys' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. At this time, Dr Reddys' Retained Earnings are fairly stable compared to the past year. Earnings Yield is likely to rise to 0.06 in 2025, whereas Price Earnings Ratio is likely to drop 16.12 in 2025. Common Stock Shares Outstanding is likely to rise to about 897.3 M in 2025. Net Income Applicable To Common Shares is likely to rise to about 59.4 B in 2025.

Hype Prediction Low Estimated High 12.92 14.35 15.78 Details

Intrinsic Valuation Low Real High 13.32 14.75 16.18 Details

Naive Forecast Low Next High 13.29 14.73 16.16 Details

4 Analysts Consensus Low Target High 13.62 14.97 16.62 Details

Note that many institutional investors and large investment bankers can move markets due to the volume of RDY assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Dr Reddys. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Dr Reddys' stock price in the short term.

Dr Reddys Earnings per Share Projection vs Actual

Actual Earning per Share of Dr Reddys refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dr Reddys Laboratories predict the company's earnings will be in the future. The higher the earnings per share of Dr Reddys, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Dr Reddys Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Dr Reddys, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dr Reddys should always be considered in relation to other companies to make a more educated investment decision.

RDY Quarterly Analyst Estimates and Surprise Metrics

Dr Reddys Corporate Directors

Additional Tools for RDY Stock Analysis